An open label evaluation of topotecan in patients with relapsed or refractory epithelial ovarian cancer - single institution experience in a developing country
Author:
- 2 November 2000
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 10 (6) , 443-448
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian CancerGynecologic Oncology, 1997
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.Journal of Clinical Oncology, 1997
- Communication with Cancer PatientsAnnals of the New York Academy of Sciences, 1997
- Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1994
- Oral etoposide is active against platinum-resistant epithelial ovarian cancer.Journal of Clinical Oncology, 1994
- Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancerGynecologic Oncology, 1992
- Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In VitroJNCI: Journal of the National Cancer Institute, 1992
- Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.Journal of Clinical Oncology, 1992
- Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.Journal of Clinical Oncology, 1992
- On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complexBiochemistry, 1989